ACOG Alpha Cognition Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1655923 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-48.6%
TTM EPS YoY8.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin99.8%
Operating margin-149.6%
Net margin-147.3%
FCF margin-152.7%
EBITDA margin-148.2%
Returns
ROE-74.2%
ROA-53.9%
ROIC (approx.)-696.4%
Asset turnover0.37x
Leverage & solvency
Liabilities / assets22.9%
Debt / equity0.00x
Current ratio7.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.78M | $6.09M | $3.53M | $2.79M | $2.84M | $1.66M | $2.93M | — |
| Cost of revenue | $482,421 | $391,057 | $248,853 | -$1.08M | $633,448 | $203,858 | $26,541 | — |
| Gross profit | $7.29M | $5.70M | $3.28M | $3.87M | $2.21M | $1.45M | $2.90M | — |
| R&D expense | $1.34M | $2.01M | $1.10M | $569,749 | $513,783 | $406,140 | $400,416 | $1.04M |
| SG&A expense | $12.38M | $11.45M | $10.26M | $9.89M | $5.11M | $9.49M | $5.09M | $1.63M |
| Operating income | -$6.43M | -$7.76M | -$8.10M | -$7.93M | -$3.42M | -$8.45M | -$3.40M | -$2.54M |
| Interest expense | — | — | — | — | — | -$644 | $8,807 | $63,120 |
| Net income | -$7.62M | -$8.79M | -$6.48M | -$6.86M | $574,380 | -$13.20M | -$1.73M | -$5.66M |
| EBITDA | -$6.31M | -$7.65M | -$8.07M | -$7.90M | -$3.41M | -$8.44M | -$3.40M | -$2.52M |
| EPS (basic) | -0.35 | -0.40 | -0.30 | — | 0.04 | -0.82 | -0.11 | — |
| EPS (diluted) | -0.35 | -0.40 | -0.32 | — | -0.29 | -0.82 | -0.11 | — |
| Weighted avg. shares (diluted) | 21.86M | 21.77M | 21.93M | — | 16.83M | 16.02M | 16.02M | — |
| Banking | ||||||||
| Provision for credit losses | — | — | — | — | — | — | — | $0 |
| Balance sheet | ||||||||
| Cash & equivalents | $37.80M | $41.38M | $54.25M | $66.05M | $35.46M | $39.46M | $45.62M | $48.56M |
| Receivables | $6.98M | $5.47M | $3.58M | $4.24M | $2.85M | $1.81M | $422,796 | — |
| Inventory | $6.41M | $6.39M | $6.04M | $5.12M | $4.50M | $875,852 | $883,376 | $615,133 |
| Current assets | $57.35M | $57.93M | $68.56M | $79.01M | $45.70M | $44.65M | $48.12M | $50.25M |
| PP&E, net | $524,255 | $374,692 | $305,479 | $328,540 | $202,754 | $72,539 | $70,452 | $27,077 |
| Intangibles | $6.13M | $6.22M | $386,036 | $391,423 | $396,809 | $402,196 | $407,582 | $412,969 |
| Total assets | $64.00M | $64.52M | $69.25M | $79.73M | $46.30M | $45.12M | $48.61M | $50.74M |
| Current liabilities | $8.04M | $6.41M | $5.43M | $9.13M | $6.83M | $3.04M | $2.81M | $3.35M |
| Total liabilities | $14.68M | $11.56M | $11.79M | $17.20M | $12.39M | $13.23M | $7.80M | $11.64M |
| Shareholders' equity | $49.32M | $54.04M | $57.46M | $62.53M | $30.79M | $26.72M | $38.50M | $39.09M |
| Shares outstanding | 21.99M | 21.77M | 21.77M | 21.74M | 16.25M | 16.02M | 16.02M | 16.02M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.85M | -$6.86M | -$11.80M | -$6.91M | -$5.29M | -$6.14M | -$2.04M | -$2.30M |
| Capital expenditure | $182,094 | $98,570 | $1,322 | $147,523 | $74,381 | $8,315 | $63,270 | — |
| Free cash flow | -$5.03M | -$6.96M | -$11.80M | -$7.05M | -$5.36M | -$6.15M | -$2.11M | — |
| Investing cash flow | -$182,094 | -$6.01M | -$1,322 | -$147,523 | -$74,381 | -$8,315 | -$63,270 | — |
| Financing cash flow | $1.45M | $0 | $800 | $37.70M | $1.36M | -$10,808 | -$834,303 | $47.12M |
| Depreciation & amortization | $120,529 | $103,586 | $29,770 | $27,123 | $12,553 | $11,614 | $7,282 | $20,395 |
| Stock-based compensation | $1.45M | $1.45M | $1.40M | $945,502 | $897,581 | $1.39M | $1.13M | $62,646 |
Free plan shows the latest 8 periods; Pro shows all 14 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.